Metropolis Healthcare Unveils Genomics Centre to Drive Precision Diagnostics
Overview
Metropolis Healthcare Limited has launched a new Centre of Genomics, a significant expansion into precision diagnostics and molecular testing across India. The initiative is supported by two CAP-accredited laboratories in Mumbai and Delhi NCR. This strategic move aims to bolster genomic research and develop advanced diagnostic platforms, targeting areas like oncology, neurology, and rare diseases, with plans to offer over 500 tests within three years.
Stocks Mentioned
Metropolis Healthcare Limited announced on Tuesday, January 13, the inauguration of its Centre of Genomics. This move marks a substantial investment to advance precision diagnostics and genomic research capabilities within India. The center's operations will be anchored by two CAP-accredited genomics laboratories situated in Mumbai and Delhi NCR.
Precision Diagnostics Push
The new genomics center is set to support critical clinical areas, including oncology, reproductive health, neurology, transplant immunology, and the diagnosis of rare diseases. Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare, stated that the center integrates diverse technological platforms with advanced data analytics and AI-driven insights. This comprehensive approach aims to establish one of India's most integrated genomic diagnostic platforms.
Technological Foundation
Metropolis Healthcare is committed to expanding its genomic test portfolio, projecting an increase from the current 220 validated assays to over 500 within the next two to three years. To achieve this, the company has deployed Illumina's NovaSeq X Series sequencing platform for research purposes. This cutting-edge technology significantly enhances throughput and accuracy in genomic analysis, reinforcing the company's next-generation sequencing infrastructure and bioinformatics capabilities.
Strategic Outlook
Dr. Kirti Chadha, Chief Scientific and Innovation Officer, highlighted that the center will translate genomic science into actionable clinical insights. Metropolis plans for the center to serve as a hub for AI-enabled analytics, continuous test development, digital integration, and support for pharmaceutical programs and global research partnerships. This expansion follows a strong Q3 business update, where Metropolis Healthcare reported a 26% year-on-year consolidated revenue increase driven by wellness checkups and specialty testing volumes.
